

Lincoln Pharma secures Indian patent

October 22, 2019 | News

The patent is awarded for its Diclofenac Rectal Spray



Lincoln Pharmaceuticals, an India based pharma company, announced that it has received Indian patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray). The patent has been awarded by the Government of India for "A Novel Liquid Rectal Spray Dosage Form Containing Diclofenac and Its Pharmaceutically Active Salts," patent number - IN320894. This patent is valid for 20 years. The company has necessary approvals from Drug Controller General of India (DCGI) and planning to launch it in the Indian market by January 2020. The company is also planning to apply for a global patent for this novel solution.

Lincoln Pharma's liquid rectal spray dosage offers faster and better absorption of the drug resulting in quick relief and speedy recovery to patients compared to the existing therapeutic options. Clinical trials conducted suggest that Diclofenac Rectal Spray is highly effective in patients suffering from pre and post operative pain, gynaecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, acute pain in renal colic and mild body ache.

Speaking on this development, Mahendra Patel, managing director, Lincoln Pharmaceuticals, said, "Globally, no liquid formulation of diclofenac for rectal administration is available. Lincoln Pharma will be the first company to introduce this novel solution aimed at better patient compliance, rapid drug release and greater bioavailability. We have developed this formulation with Diclofenac Sodium BP 25% W/V, each squirt delivers Diclofenac Sodium 50 mg, non-steroidal anti-inflammatory agent (NSAIDs). Due to this innovation, now patients can get far better results by using Diclofenac Rectal Spray as compared to the

existing Diclofenac Suppository available in the market. We are planning to apply for a Global patent for this solution."